Summary We studied the effect of ovarian cancer and its chemotherapy on the urinary excretion of prostacyclin (PGI2) and thromboxane A2 (TxA2) hydration and metabolic products. In six patients we measured 6-keto-PGF,a and 2,3-dinor-6-keto-PGF,. (PGI2 products) and thromboxane B2 (TxB2) and 2,3-dinor-TxB2 (TxA2 products) by HPLC followed by radioimmunoassay before, during and after the combined infusion of cisplatin, 4'epi-adriamycin and cyclophosphamide. Before the first cytostatic infusion, the urinary excretion of prostanoids was on average 4.4-5.8 times higher than in patients with ovarian endometriosis (n= 19). The infusion of cytostatics led to a 50-120% rise in the excretion of prostanoids during the first post-infusion 9 hours, but in the subsequent 10 hours their ouput was 25-45% below the initial value and remained low for at least 2 weeks. Following repetitive courses of cytostatics (2-4 per patient), prostanoid excretion tended to normalise. These data suggest that ovarian cancer is associated with increased production of PGI2 and TxA2, and that cytostatics suppress this production. This may be of biological significance in tumour behaviour and in the effect of cytostatics.
Arachidonic acid metabolites can modulate cancer promotion, growth, and spread (Karmali, 1983 (Karmali, , 1987 Bennett, 1984; Deliconstantinos, 1987) . Vasodilator, anti-aggregatory prostacyclin (PG12) and vasoconstrictor, pro-aggregatory thromboxane A2 (TxA2) are especially important in this regard, since their balance may determine, at least partly, the potential of some cancers to grow and spread. This theory has been supported by some studies (Honn & Meyer, 1981 Honn et al., 1983a , but also disputed by other data (Stamford et al., 1986) . That prostaglandins and prostanoids may be of significance for tumour behaviour gains support from the data that prostaglandin synthesis inhibitors increase the survival time of mice transplanted with mammary carcinoma (Bennett et al., 1982) . Ovarian cancer grows aggressively, sends out metastases early and is often accompanied by deep vein thrombosis (Fox, 1985) ; the latter phenomenon may well be a sign of disturbed PGI2/TxA2 balance. We showed recently that this cancer, as compared with healthy ovarian tissue, produces in vitro an 11-fold excess of 6-ketoprostagladin Fl,, (6-keto-PGFI,, the hydration product of PGI2) and a 30-fold excess of thromboxane B2 (TxB2, the hydration product of TxA2) (Aitokallio-Tallberg et al., 1988) , and that patients with ovarian cancer excrete increased amounts of 6-keto-PGFIr. in their urine (Aitokallio-Tallberg et al., 1987) .
A combination of cisplatin, 4'epi-adriamycin and cyclophosphamide is most often used for treating advanced ovarian malignancy (Hainsworth et al.,1988) . These agents inhibit the division of cancer cells by disturbing DNA double-helix formation (Chabner, 1982) . Prostanoids can influence cell growth and division, perhaps through cyclic AMP (Gorman et al., 1977; Thaler-Dao et al., 1984) .
It is well established that cytostatics can release various classic prostaglandins in vitro (Berstock et al., 1979; Bennett et al., 1982) , but there are only a few data on the effect of cytostatics on PGI2 and TxA2 production. High circulating levels of 6-keto-PGFI,, and TxB2 in patients with gynaecological malignancies Alam et al., 1982; Sundstrom et al., 1986) decreased following administration of cytostatics by 30-40% or by 52% (Alam et al., 1982) .
Currently, PGI2 and TxA2 production in vivo is best assessed by measuring their urinary degradation products Fischer et al., 1986; . The present study was designed to study the effect of cisplatin, 4'epi-adriamycin and cyclophosphamide in combination on the urinary output of PG12 and TxA2 degradation products in patients with ovarian cancer.
Patients and methods
Five patients with ovarian serous adenocarcinoma and one with ovarian endometrioid adenocarcinoma were studied. They were between 15 and 73 years of age (mean 51); three were premenopausal and three post-menopausal. In two women cancer was limited to the ovaries, but it had spread to stage III -IV in four patients. Five patients had an elevated (>65 IU ml-') cancer antigen 125 All cancer patients received the same treatment, beginning two weeks after surgery, with intravenous injection of cyclophosphamide (500 mg m-2) and 4'epi-adriamycin (40 mg m-2). Physiological saline (1000 ml) was infused concomitantly to guarantee adequate diuresis. Two or three hours later cisplatin (50 mg m-2) was started as an intravenous infusion over 5-7 hours; mannitol (15%, 500 ml i.v.) and furosemide (20 mg i.m.) were also given. This regimen was repeated on two to four occasions at 4-week intervals, and altogether 19 courses were studied.
Urines were collected for: (1) 4-6 hours before the start of cytostatics; (2) 5 hours from the start of the treatment; (3) 4 hours after the second sample; (4) 10 hours after the third sample; (5) 4-6 hours 2 weeks later. In addition we collected samples from four patients 4 weeks after the last cytostatic treatment.
The non-malignant control group collected their 24-hour urines the day before laparoscopy. During the study no subject took any drug (except for cytostatics) known to affect prostanoid synthesis.
A 100 ml sample of each urine was frozen and stored at -25C for 2-5 months until assayed for products of PGI2 (6-keto-PGFir. and 2,3-dinor-6-keto-PGF1,) and TxA2 (TxB2 and 2,3-dinor-TxB2). This storage does not affect the prostanoids (Aitokallio-Tallberg et al., 1988) . In brief, 10ml of acidified urine (pH 3.0, IM HCI) were passed through Sep Pak C18 cartridges (Waters Association, Milford, USA). Retained prostanoids were eluted with ethyl acetate, evaporated to dryness, and put through HPLC (water/ acetonitrile/acetic acid, 69.95:30.0:0.05, 2 ml min-'). After 2 min the first fraction (I) was collected over 1.5 min; this contained 6-keto-PGFIj and dinor-TXB2. The second fraction (II), collected for 3.5 min starting 0.25 min after the first one, contained dinor-6-keto-PGFIr. and TxB2. Fraction I was assayed for 6-keto-PGF1,, using 3H-6-keto-PGF10, as the tracer, 6-keto-PGF,,, as the standard, and an antibody raised against 6-keto-PGF1. in rabbits . For dinor-TxB2, 3H-TxB2 was used as the tracer, dinor-TxB2 as the standard and rabbit TxB2 as the antibody (Viinikka & Ylikorkala, 1980) because this antibody has approximately 40% cross-reactivity with 2,3-dinor-TxB2. Fraction II was assayed for TxB2 using 3H-TxB2 as the tracer, TxB2 as the standard and TxA2 antibody (Viinikka & Ylikorkala, 1980) . For dinor-6-keto-PGFIm we used 3H-6-keto-PGFI, as the tracer, dinor-6-keto-PGFI,, as the standard and the 6-keto-PGFI. antibody because this antibody has approximately 20% crossreactivity with 2,3-dinor-6-keto-PGFIg. The details of the methods are give elsewhere . Pros- tanoid excretion is expressed as pg min-'.
At the end of each urine collection, serum and urine creatinine were measured and the creatinine clearance determined.
The prostanoid excretion data are given as means ± s.e. The significances of the difference were analysed by Student's t test for paired and unpaired data as appropriate. To illustrate better the effect of cytostatics, the values during their administration are given as percentages of the pretreatment levels.
Results
Before cytostatics were given, the prostanoid excretion in cancer patients was clearly higher than in the patients with endometriosis (Table I ). The increases were: 6-keto-PGFIr. 4.9-fold (P <0.0025), dinor-6-keto-PGFI, 4.4-fold (P<0.002), TxB2 5.8-fold (P<0.0125) and dinor-TxB2 4.5-fold (P <0.0005).
The cytostatic infusions were accompanied by a 50-120% rise in the 5-h excretion of PGI2 and TxA2 products ( Figure  1 ). This stimulation was strongest for 6-keto-PGFIc and TxB2 excretion. Between 9 and 19 h after the start of infusion the excretion for all prostanoids was 35-45% below the pretreatment levels. This reduction persisted for at least 2 weeks (Figure 1) . The pattern of urinary prostanoid excretion during infusion of cytostatics was constant from one course to another.
Overall the amounts of PGI2 products fell after repetitive courses with chemotherapy (Table I) . This was not the case in the output of TxA2 products which on average did not change when the data following all cytostastic courses were considered as a whole (Table I) . However, when only the last cytostastic course was considered, the excretion of TxA2 products decreased in four patients who responded favourably to cytostatics, but remained high in two patients who showed no response to treatment. There was also a good correlation between decreases in serum CA-125 or CEA levels and in urinary excretion of TxA2 products (Table II) .
The mean creatinine clearance was approximately 20 ± 5% lower 9 and 19 h after giving the cytostatics (P = 0.06, Figure  1 ). No significant relationship was seen between individual prostanoid excretion and creatinine clearance, occurrence of side-effects, or counts of leucocytes and platelets. 80% reduction in tumour size The excretion ofprostacyclin products decreased in all patients, but the excretion of thromboxane products decreased only in patients who responded favourably to treatment (patients 1, 3, 5 and 6).
Discussion
Through their effects on vascular wall -platelet interaction, PGI2 and TxA2 may be important in cancer metastasis and spread. It is generally thought that PGI2 or its dominance over TxA2 should prevent metastasis (Honn et al., , 1983b , but this theory has also been disputed (Stamford et al., 1986) . The picture may be partly unclear due to difficulties in assessing PGI2 and TxA2 production in vivo. Currently, in vivo PGI2 and TxA2 synthesis is usually studied by measuring their urinary products Fischer et al., 1986; Ylikorkala et al., 1986) . Urinary 2,3-dinor-6-keto-PGFIr. is considered the best index of systemic PGI2 production (Rosenkranz et al., 1980; Brash et al., 1983 ), whereas urinary 6-keto-PGF1,, may originate primarily from the kidneys (Patrono et al., 1982) . Circulating platelets are the main source of urinary TxB2 and 2,3-dinor-TxB2 (Roberts et al., 1981) , although renal tissue may also produce them, particularly TxB2 . In the present work we measured all four of these prostanoids.
The main purpose of this study was to evaluate the effects of cytostatics on PGI2 and TxA2 pr(duction. Because interindividual variations in prostanoid excretion are large (Fischer et al., 1986) , we studied the effect of repetitive courses of cytostatics. Previously we found increased urinary excretion of 6-keto-PGF1,, in patients with ovarian malignancy (Aitokallio-Tallberg et al., 1987) . We now show that in these patients 2,3-dinor-6-keto-PGFjg, TxB2 and 2,3-dinor-TxB2 are also excreted excessively into urine. These rises are probably in part related to the cancer, because they are higher than those in the control group of patients with endometriosis who may also have increased PGI2 and TxA2 production (Dawood et al., 1984; Ylikorkala et al., 1984) . We assume that the excess prostanoids arise either from the cancer cells (Aitokallio-Tallberg et al., 1988) , or possibly in part elsewhere in the body as a result of paraneoplastic changes. The question of the role of prostanoid stimulation in the growth and spread of ovarian cancer remains open.
Cytostatic therapy of ovarian cancer, applied in clinical routine (Hainsworth et al., 1988) , led similarly to a rise and then a fall in the urinary output of PGI2 and TxA2 products. Because the treatment did not alter renal function significantly, the changes in urinary prostanoids presumably reflect altered synthesis and/or release of PGI2 and TxA2 during cytostatic infusion. Cytostatics damage and/or kill both cancerous and healthy cells, which may explain the initial rise in prostanoid output in our work. Perhaps cell death was so marked that it was reflected in later suppression of prostanoid output. In the case of TxA2 suppression, a decrease in platelet count induced by the cytostatics might be a factor, although individual excretion and platelet counts did not correlate. Furthermore, prostanoid excretion started to decrease sooner than did platelet numbers, suggesting that thrombopenia does not explain the suppression of TxA2 products.
We do not know which of the cytostatics caused prostanoid changes. Although cytostatics, especially cisplatin, affect renal tissue and function (Von Hoff & Rosencweig, 1979) , creatinine clearance in out patients showed little or no change. Furosemide could also have been a factor, because it was reported to increase the output of PGI2 and TxA2 products (Wilson et al., 1983) , but this was not confirmed by others (Mackay et al., 1984; Franchi et al., 1987) .
The most important finding of the present work was the decrease in excretion of PGI2 and TxA2 products in patients responding well to cytostatics, and the normalisation of excretion in many patients concomitantly with reduction in tumour mass. This supports the role of prostanoids in cancer (Honn & Meyer, 1981; Bennett, 1984) . Of the two prostanoids studied, TxA2 may be more important for the progress of ovarian cancer, since it remained unchanged in patients who did not respond to chemotherapy.
In conclusion, patients with ovarian cancer excreted more urinary PG12 and TxA2 products than did patients with endometriosis. A combination of cisplatin, cyclophosphamide and 4'epi-adriamycin initially stimulated these outputs, but after repetitive courses caused a constant suppression. This study was supported by grants from The Cancer Research Foundation and Sigrid Juselius Foundation.
